KOENZİM Q0 İNSAN KRONİK MYELOİD LÖSEMİ K562 HÜCRELERİNİN PROLİFERASYONUNU ENGELLER VE MAPK VE AKT SİNYAL YOLAKLARINI MODÜLE EDER

Öz

Amaç: Bu çalışma, insan kronik miyeloid lösemi K562 hücre hattında koenzim Q0'ın (CoQ0) antiproliferatif ve proapoptotik etkilerini değerlendirmiştir. Gereç ve Yöntem: CoQ0'ın insan kronik miyeloid lösemi K562 hücre hattındaki sitotoksik etkisi, MTT testi ile belirlendi. Kaspaz-3 aktivitesi, apoptozis, MAPK ve AKT sinyal yolağı ile ilişkili proteinlerin ekspresyonu sırasıyla enzimatik analiz ve western blot analizi ile belirlendi. Sonuç ve Tartışma: Sonuçlar, CoQ0’ın K562 hücre canlılığını 5 μM ve daha yüksek konsantrasyonlarda inhibe ettiğini ve Bax protein ekspresyonunu, 12.5 μM konsantrasyonunda önemli ölçüde azalttığını göstermiştir, ancak CoQ0 kaspaz 3 aktivitesini ve Bcl-2 protein ekspresyonunu önemli ölçüde etkilemedi. p-c-Raf (Ser259) protein ekspresyonu, 12.5 μM CoQ0'da önemli ölçüde azaldı. K562 hücre hattında, 10 μM CoQ0, p38 MAPK'nın fosforilasyonunu önemli ölçüde indükledi ve 12,5 μM CoQ0, p-ERK1/2 protein ekspresyonunda anlamlı olmayan bir azalmaya neden oldu. İlginç bir şekilde, 12.5 μM CoQ0 K562 hücrelerinde Akt (Ser473) fosforilasyonu azalttı, ancak p-Akt (Thr308) protein ekspresyonunda gruplar arasında herhangi bir farklılık gözlenmedi. Sonuç olarak, CoQ0, K562 hücrelerinin proliferasyonunu inhibe etti ve c-Raf (Ser259), Akt (Ser473) fosforilasyonunu baskıladı, ancak ERK1/2 fosforilasyonuna etki etmedi. CoQ0'ın antikanser etkisinin altında yatan moleküler mekanizmalara yeni bakış açıları sağlamak ve kronik miyeloid lösemi tedavi stratejilerini geliştirmek için daha fazla araştırmaya hala ihtiyaç bulunmaktadır.

Anahtar Kelimeler

• Koenzim Q0
• kronik miyeloid lösemi
• K562

COENZYME Q0 INHIBITS CELL PROLIFERATION AND MODULATES MAPK AND AKT SIGNALLING PATHWAYS IN HUMAN CHRONIC MYELOID LEUKEMIA K562 CELLS

Öz

Objective: This study evaluated the antiproliferative and pro-apoptotic effects of coenzyme Q0 (CoQ0) in human chronic myeloid leukemia K562 cell line. Material and Method: The cytotoxic effect of CoQ0 on human chronic myeloid leukemia cell line, K562 was determined by MTT test. The activity of caspase-3, expression of proteins involved in apoptosis, MAPK and AKT signaling pathways were determined with enzymatic assay and western blot analysis, respectively. Result and Discussion: Results showed that CoQ0 inhibited cell viability of K562 cells at 5 μM and higher concentrations and Bax protein expression was significantly decreased at 12.5 μM concentration of CoQ0. However, CoQ0 did not significantly affect caspase 3 activity and Bcl-2 protein expression. p-c-Raf (Ser259) protein expression was significantly decreased at 12.5 μM of CoQ0. Treatment with 10 μM of CoQ0 induced significantly phosphorylation of p38 MAPK and 12.5 μM CoQ0 caused a nonsignificant decrease in p-ERK1/2 protein expression in K562 cell line. Interestingly, in K562 cells, phosphorylation of Akt (Ser473) was diminished at 12.5 μM of CoQ0, with no change observed in p-Akt (Thr308) protein expression among groups. In conclusion, CoQ0 inhibited cell proliferation and suppressed phosphorylation of c-Raf (Ser259), Akt (Ser473), but not ERK1/2 in K562 cells. There is still a need for new insights into the anticancer mechanisms of CoQ0 and develop treatment strategies for chronic myeloid leukemia.

Anahtar Kelimeler

• Chronic myeloid leukemia
• coenzyme Q0
• K562

Kaynakça

1. 1. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., Kantarjian, H.M. (1999). The biology of chronic myeloid leukemia. New England Journal of Medicine, 341(3), 164-172. [CrossRef]
2. 2. Chereda, B., Melo, J.V. (2015). Natural course and biology of CML. Annals of Hematology, 94(Suppl 2), S107-121. [CrossRef]
3. 3. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., Sawyers, C.L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344(14), 1031-1037. [CrossRef]
4. 4. Kantarjian, H.M., Talpaz, M. (2001). Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias. Seminars in Oncology, 28(5 Suppl 17), 9-18. [CrossRef]
5. 5. Mohamed, A.N., Pemberton, P., Zonder, J., Schiffer, C.A. (2003). The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clinical Cancer Research, 9(4), 1333-1337.
6. 6. Somers-Edgar, T.J., Rosengren, R.J. (2009). Coenzyme Q0 induces apoptosis and modulates the cell cycle in estrogen receptor negative breast cancer cells. Anticancer Drugs, 20(1), 33-40. [CrossRef]
7. 7. MacDonald, M.J., Husain, R.D., Hoffmann-Benning, S., Baker, T.R. (2004). Immunochemical identification of coenzyme Q0-dihydrolipoamide adducts in the E2 components of the alpha-ketoglutarate and pyruvate dehydrogenase complexes partially explains the cellular toxicity of coenzyme Q0. Journal of Biological Chemistry, 279(26), 27278-27285. [CrossRef]
8. 8. Chung, C.H., Yeh, S.C., Chen, C.J., Lee, K.T. (2014). Coenzyme Q0 from Antrodia cinnamomea in submerged cultures induces reactive oxygen species-mediated apoptosis in A549 human lung cancer cells. Evidence-Based Complementary and Alternative Medicine, 2014, 246748. [CrossRef]

9. 9. MacDonald, M.J. (1991). Stimulation of insulin release from pancreatic islets by quinones. Bioscience Reports, 11(3), 165-170. [CrossRef]
10. 10. Yang, H.L., Korivi M, Lin M.W, Chen S.C, Chou C.W, Hseu Y.C. (2015). Anti-angiogenic properties of coenzyme Q0 through downregulation of MMP-9/NF-kappaB and upregulation of HO-1 signaling in TNF-alpha-activated human endothelial cells. Biochemical Pharmacology, 98(1), 144-156. [CrossRef]
11. 11. Yang, H.L., Lin, M.W., Korivi, M., Wu, J.J., Liao, C.H., Chang, C.T., Liao, J.W., Hseu, Y.C. (2016). Coenzyme Q0 regulates NFkappaB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies. Biochimica et Biophysica Acta, 1859(2), 246-261. [CrossRef]
12. 12. Yang, H.L., Thiyagarajan, V., Shen, P.C., Mathew, D.C., Lin, K.Y., Liao, J.W., Hseu, Y.C. (2019). Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis. Journal of Experimental&Clinical Cancer Research, 38(1), 186. [CrossRef]
13. 13. Hseu, Y.C., Thiyagarajan, V., Tsou, H.T., Lin, K.Y., Chen, H.J., Lin, C.M., Liao, J.W., Yang, H.L. (2016). In vitro and in vivo anti-tumor activity of CoQ0 against melanoma cells: Inhibition of metastasis and induction of cell-cycle arrest and apoptosis through modulation of Wnt/beta-catenin signaling pathways. Oncotarget, 7(16), 22409-22426. [CrossRef]
14. 14. Wang, H.M., Yang, H.L., Thiyagarajan, V., Huang, T.H., Huang, P.J., Chen, S.C., Liu, J.Y., Hsu, L.S., Chang, H.W., Hseu, Y.C. (2017). Coenzyme Q0 enhances ultraviolet B-induced apoptosis in human estrogen receptor-positive breast (MCF-7) cancer cells. Integrative Cancer Therapies, 16(3), 385-396. [CrossRef]
15. 15. Esaka, Y., Nagahara, Y., Hasome, Y., Nishio, R., Ikekita, M. (2005). Coenzyme Q2 induced p53-dependent apoptosis. Biochimica et Biophysica Acta, 1724(1-2), 49-58. [CrossRef]
16. 16. Devun, F., Walter, L., Belliere, J., Cottet-Rousselle, C., Leverve, X., Fontaine, E. (2010). Ubiquinone analogs: A mitochondrial permeability transition pore-dependent pathway to selective cell death. PLOS One, 5(7), e11792. [CrossRef]
17. 17. Bold, R.J., Termuhlen, P.M., McConkey, D.J. (1997). Apoptosis, cancer and cancer therapy. Surgical Oncology, 6(3), 133-142. [CrossRef]
18. 18. Kim, E.K., Kwon, K.B., Shin, B.C., Seo, E.A., Lee, Y.R., Kim, J.S., Park, J.W., Park, B.H., Ryu, D.G. (2005). Scopoletin induces apoptosis in human promyeloleukemic cells, accompanied by activations of nuclear factor kappaB and caspase-3. Life Sciences, 77(7), 824-836. [CrossRef]
19. 19. Zhou, Y., Liu, Q.H., Liu, C.L., Lin, L. (2015). Calycosin induces apoptosis in human ovarian cancer SKOV3 cells by activating caspases and Bcl-2 family proteins. Tumour Biology, 36(7), 5333-5339. [CrossRef]
20. 20. Brunelle, J.K., Letai, A. (2009). Control of mitochondrial apoptosis by the Bcl-2 family. Journal of Cell Science, 122(Pt 4), 437-441. [CrossRef]
21. 21. Schaeffer, H.J., Weber, M.J. (1999). Mitogen-activated protein kinases: Specific messages from ubiquitous messengers. Molecular and Cellular Biology, 19(4), 2435-2444. [CrossRef]
22. 22. Platanias, L.C. (2003). Map kinase signaling pathways and hematologic malignancies. Blood, 101(12), 4667-4679. [CrossRef]
23. 23. Dong, C., Davis, R.J., Flavell, R.A. (2002). MAP kinases in the immune response. Annual Review of Immunology, 20, 55-72. [CrossRef]
24. 24. Denhardt, D.T. (1996). Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: The potential for multiplex signalling. Biochemical Journal, 318(Pt 3), 729-747. [CrossRef]
25. 25. Widmann, C., Gibson, S., Jarpe, M.B., Johnson, G.L. (1999). Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiological Reviews, 79(1), 143-180. [CrossRef]
26. 26. Zhang, W., Liu, H.T. (2002). MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Research,12(1), 9-18. [CrossRef]
27. 27. Zhang, Z., Zhou, X., Shen, H., Wang, D., Wang, Y. (2009). Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: Evidence from an in vitro study. BMC Medicine, 7, 41. [CrossRef]
28. 28. Beeram, M., Patnaik, A., Rowinsky, E.K. (2005). Raf: A strategic target for therapeutic development against cancer. Journal of Clinical Oncology, 23(27), 6771-6790. [CrossRef]
29. 29. Lopez-Bergami, P., Huang, C., Goydos, J.S., Yip, D., Bar-Eli, M., Herlyn, M., Smalley, K.S., Mahale, A., Eroshkin, A., Aaronson, S., Ronai, Z. (2007). Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell, 11(5), 447-460. [CrossRef]
30. 30. Mirmohammadsadegh, A., Mota, R., Gustrau, A., Hassan, M., Nambiar, S., Marini, A., Bojar, H., Tannapfel, A., Hengge, U.R. (2007). ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. Journal of Investigative Dermatology, 127(9), 2207-2215. [CrossRef]
31. 31. Mendes, O., Kim, H.T., Lungu, G., Stoica, G. (2007). MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clinical&Experimental Metastasis, 24, 341-351. [CrossRef]
32. 32. Fransecky, L., Mochmann, L.H., Baldus, C.D. (2015). Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Molecular and Cellular Therapies, 3, 2. [CrossRef]
33. 33. Kawauchi, K., Ogasawara, T., Yasuyama, M., Otsuka, K., Yamada, O. (2009). Regulation and importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies. Anticancer Agents in Medicinal Chemistry, 9(9), 1024-1038. [CrossRef]
34. 34. Min, Y.H., Eom, J.I., Cheong, J.W., Maeng, H.O., Kim, J.Y., Jeung, H.K., Lee, S.T., Lee, M.H., Hahn, J.S., Ko, Y.W. (2003). Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: Its significance as a prognostic variable. Leukemia, 17(5), 995-997. [CrossRef]
35. 35. Kornblau, S.M., Tibes, R, Qiu, Y.H., Chen, W., Kantarjian, H.M., Andreeff, M., Coombes, K.R., Mills, G.B. (2009). Functional proteomic profiling of AML predicts response and survival. Blood, 113(1), 154-164. [CrossRef]
36. 36. Pei, R., Si, T., Lu, Y., Zhou, J.X., Jiang, L. (2018). Salvianolic acid A, a novel PI3K/Akt inhibitor, induces cell apoptosis and suppresses tumor growth in acute myeloid leukemia. Leukemia&Lymphoma, 59(8), 1959-1967. [CrossRef]
37. 37. Zhou, Y., Ho, W.S. (2014). Combination of liquiritin, isoliquiritin and isoliquirigenin induce apoptotic cell death through upregulating p53 and p21 in the A549 non-small cell lung cancer cells. Oncology Reports, 31(1), 298-304. [CrossRef]
38. 38. Hseu, Y.C., Tsai, T.J., Korivi, M., Liu, J.Y., Chen, H.J., Lin, C.M., Shen, Y.C., Yang, H.L. (2017). Antitumor properties of Coenzyme Q0 against human ovarian carcinoma cells via induction of ROS-mediated apoptosis and cytoprotective autophagy. Scientific Reports, 7(1), 8062. [CrossRef]
39. 39. Elumalai, P., Gunadharini, D.N., Senthilkumar, K., Banudevi, S., Arunkumar, R., Benson, C.S., Sharmila, G., Arunakaran, J. (2012). Induction of apoptosis in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway. Toxicology Letters, 215(2), 131-142. [CrossRef]
40. 40. Green, D.R. (2000). Apoptotic pathways: paper wraps stone blunts scissors. Cell, 102(1), 1-4. [CrossRef]
41. 41. McIlwain, D.R., Berger, T., Mak, T.W. (2013). Caspase functions in cell death and disease. Cold Spring Harbor Perspectives in Biology, 5(4), a008656. [CrossRef]
42. 42. Yang, X., Zheng, F., Xing, H., Gao, Q., Wei, W., Lu, Y., Wang, S., Zhou, J., Hu, W., Ma, D. (2004). Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 130(7), 423-428. [CrossRef]
43. 43. Kim, R. (2005). Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochemical and Biophysical Research Communication, 333(2), 336-343. [CrossRef]
44. 44. Mayorga, M., Bahi, N., Ballester, M., Comella, J.X., Sanchis, D. (2004). Bcl-2 is a key factor for cardiac fibroblast resistance to programmed cell death. Journal of Biological Chemistry, 279(33), 34882-34889. [CrossRef]
45. 45. Goldsmith, C.D., Bond, D.R., Jankowski, H., Weidenhofer, J., Stathopoulos, C.E., Roach, P.D., Scarlett, C.J. (2018). The olive biophenols oleuropein and hydroxytyrosol selectively reduce proliferation, influence the cell cycle, and induce apoptosis in pancreatic cancer cells. International Journal of Molecular Sciences, 19(7), 1937. [CrossRef]
46. 46. Roberts, P.J., Der, C.J. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26(22), 3291-3310. [CrossRef]
47. 47. Miyata, Y., Nishida, E. (1999). Distantly related cousins of MAP kinase: Biochemical properties and possible physiological functions. Biochemical and Biophysical Research Communication, 266(2), 291-295. [CrossRef]
48. 48. Schulze-Bergkamen, H., Krammer, P.H. (2004). Apoptosis in cancer-implications for therapy. Seminars in Oncology, 31(1), 90-119. [CrossRef]
49. 49. Xia, Z., Dickens, M., Raingeaud, J., Davis, R.J., Greenberg, M.E. (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 270(5240), 1326-1331. [CrossRef]
50. 50. Weir, N.M., Selvendiran, K., Kutala, V.K., Tong, L., Vishwanath, S., Rajaram, M., Tridandapani, S., Anant, S., Kuppusamy, P. (2007). Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biology&Therapy, 6(2), 178-184. [CrossRef]
51. 51. Shinojima, N., Yokoyama, T., Kondo, Y., Kondo, S. (2007). Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy, 3(6), 635-637. [CrossRef]
52. 52. Juretic, N., Santibanez, J.F., Hurtado, C., Martinez, J. (2001). ERK 1,2 and p38 pathways are involved in the proliferative stimuli mediated by urokinase in osteoblastic SaOS-2 cell line. Journal of Cellular Biochemistry, 83(1), 92-98. [CrossRef]
53. 53. Pugazhenthi, S., Miller, E., Sable, C., Young, P., Heidenreich, K.A., Boxer, L.M., Reusch, J.E. (1999). Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein. Journal of Biological Chemistry, 274(39), 27529-27535. [CrossRef]
54. 54. Wang, Y., Huang, S., Sah, V.P., Ross, J.Jr., Brown, J.H., Han, J., Chien, K.R. (1998). Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. Journal of Biological Chemistry, 273(4), 2161-2168. [CrossRef]
55. 55. Li, L., Zhao, G.D., Shi, Z., Qi, L.L., Zhou, L.Y., Fu, Z.X. (2016). The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncology Letters, 12(5), 3045-3050. [CrossRef]
56. 56. Dhillon, A.S., Meikle, S., Yazici, Z., Eulitz, M., Kolch, W. (2002). Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO Journal, 21(1-2), 64-71. [CrossRef]
57. 57. Rommel, C., Clarke, B.A., Zimmermann, S., Nunez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G.D., Glass, D.J. (1999). Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science, 286(5445), 1738-1741. [CrossRef]
58. 58. Corona, G., Deiana, M., Incani, A., Vauzour, D., Dessi, M.A., Spencer, J.P. (2007). Inhibition of p38/CREB phosphorylation and COX-2 expression by olive oil polyphenols underlies their anti-proliferative effects. Biochemical and Biophysical Research Communication, 362(3), 606-611. [CrossRef]
59. 59. Wang, N., Li, D.Y., Niu, H.Y., Zhang, Y., He, P., Wang, J.H. (2013). 2-Hydroxy-3-methylanthraquinone from Hedyotis diffusa Willd induces apoptosis in human leukemic U937 cells through modulation of MAPK pathways. Archives of Pharmacal Research, 36(6), 752-758. [CrossRef]
60. 60. Fu, Y., Zhang, Y., Gao, M., Quan, L., Gui, R., Liu, J. (2016). Alisertib induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Molecular Medicine Reports, 14(1), 394-398. [CrossRef]